|
Products |
| Products |
|
Diseases |  |
News |  |
| 12345678910111213...39313932» |
- | Yescarta (axicabtagene ciloleucel) / Gilead
Trial primary completion date: ZUMA-24: Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma (clinicaltrials.gov) - Oct 4, 2024
P2, N=30, Active, not recruiting, Sponsor: Kite, A Gilead Company
Trial primary completion date: Mar 2026 --> Sep 2024
- | tiragolumab (RG6058) / Roche, Tecentriq (atezolizumab) / Roche
Trial primary completion date: An Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Gastric or Gastroesophageal Junction Carcinoma (clinicaltrials.gov) - Oct 4, 2024
P1/2, N=40, Active, not recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Mar 2026 --> Sep 2024 Trial primary completion date: Dec 2024 --> Jun 2025
- || Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial primary completion date, Combination therapy, Monotherapy, Metastases: Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009) (clinicaltrials.gov) - Oct 4, 2024
P2, N=408, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
Trial primary completion date: Dec 2024 --> Jun 2025 Trial primary completion date: Sep 2025 --> May 2024
- | Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Trial primary completion date, Metastases: A Phase II Trial of PD-L1 Therapy Combined with Anti-VEGF Therapy in Unresectable or Metastatic Melanoma (clinicaltrials.gov) - Oct 4, 2024
P2, N=30, Recruiting, Sponsor: Elizabeth Buchbinder, MD
Trial primary completion date: Sep 2025 --> May 2024 Trial primary completion date: Sep 2024 --> Dec 2024
- Keytruda (pembrolizumab) / Merck (MSD)
The association between body mass index and overall survival among metastatic breast cancer patients receiving pembrolizumab (Grand Ballroom AB - George R. Brown Convention Center) - Oct 4, 2024 - Abstract #SITC2024SITC_1874;
Full Regular Abstract, Young Investigator Award (YIA), Immune Engineering Abstracts, and Late-breaking Abstract - Clinical Only (LBA) content will be embargoed until Nov. 5, 2024 at 8 a.m. CT / 9 a.m. ET
- acasunlimab (GEN1046) / Genmab
Acasunlimab combined with PD-1 blockade elicits complementary immune-modulatory effects and enhances anti-tumor activity in preclinical models (Grand Ballroom AB - George R. Brown Convention Center) - Oct 4, 2024 - Abstract #SITC2024SITC_1839;
Full Regular Abstract, Young Investigator Award (YIA), Immune Engineering Abstracts, and Late-breaking Abstract - Clinical Only (LBA) content will be embargoed until Nov. 5, 2024 at 8 a.m. CT / 9 a.m. ET
- Bavencio (avelumab) / EMD Serono, Erbitux (cetuximab) / Eli Lilly
Combination of NY-ESO-1 TCR-T cells secreting SiRP-alpha decoys with Avelumab and Cetuximab augments tumor cell phagocytosis by macrophages (Grand Ballroom AB - George R. Brown Convention Center) - Oct 4, 2024 - Abstract #SITC2024SITC_1824;
Full Regular Abstract, Young Investigator Award (YIA), Immune Engineering Abstracts, and Late-breaking Abstract - Clinical Only (LBA) content will be embargoed until Nov. 5, 2024 at 8 a.m. CT / 9 a.m. ET
- Keytruda (pembrolizumab) / Merck (MSD), CUE-101 / Cue Biopharma, LG Chem
A phase 1 dose-escalation and expansion study of CUE-101 as monotherapy and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck squamous cell cancer (Grand Ballroom AB - George R. Brown Convention Center) - Oct 4, 2024 - Abstract #SITC2024SITC_1805;
- Imfinzi (durvalumab) / AstraZeneca
Differential Gene Enrichment in Response to Durvalumab and Metformin in Head and Neck Cancer Patients: The Role of the Neutrophil to Lymphocyte Ratio (NLR) and Epithelial Mesenchymal Transition (EMT) (Grand Ballroom AB - George R. Brown Convention Center) - Oct 4, 2024 - Abstract #SITC2024SITC_1779;
Full Regular Abstract, Young Investigator Award (YIA), Immune Engineering Abstracts, and Late-breaking Abstract - Clinical Only (LBA) content will be embargoed until Nov. 5, 2024 at 8 a.m. CT / 9 a.m. ET
- WTX212 / Westlake Therap
Erythrocyte-?PD-1 conjugates suppress cancers with resistance to checkpoint blockade immunotherapy (Grand Ballroom AB - George R. Brown Convention Center) - Oct 4, 2024 - Abstract #SITC2024SITC_1773;
Full Regular Abstract, Young Investigator Award (YIA), Immune Engineering Abstracts, and Late-breaking Abstract - Clinical Only (LBA) content will be embargoed until Nov. 5, 2024 at 8 a.m. CT / 9 a.m. ET
- LMY-920 / Luminary Therap
A Phase 1 Study of Novel Transposon-Based BAFF CAR-T cells (LMY-920) for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (Grand Ballroom AB - George R. Brown Convention Center) - Oct 4, 2024 - Abstract #SITC2024SITC_1728;
5, 2024 at 8 a.m. CT / 9 a.m. ET Co-organized by the Society for Immunotherapy of Cancer (SITC) and American Society of Hematology (ASH).
- Yescarta (axicabtagene ciloleucel) / Gilead
Serum Interleukin-2 levels in the first 24-72 hours post CD19 CAR T cell infusion is a robust biomarker of CAR T cell expansion in Leukemia and Lymphoma Patients treated with Axi-cel or Brexu-cel (Exhibit Halls AB - George R. Brown Convention Center) - Oct 4, 2024 - Abstract #SITC2024SITC_1715;
Full Regular Abstract, Young Investigator Award (YIA), Immune Engineering Abstracts, and Late-breaking Abstract - Clinical Only (LBA) content will be embargoed until Nov. 5, 2024 at 8 a.m. CT / 9 a.m. ET
- magrolimab (ONO-7913) / Ono Pharma
Biomarker Analysis of Magrolimab plus Docetaxel in Patients with 2L+ mNSCLC from ELEVATE-Lung and UC, a Phase 2 multicohort study (Exhibit Halls AB - George R. Brown Convention Center) - Oct 4, 2024 - Abstract #SITC2024SITC_1704;
Full Regular Abstract, Young Investigator Award (YIA), Immune Engineering Abstracts, and Late-breaking Abstract - Clinical Only (LBA) content will be embargoed until Nov. 5, 2024 at 8 a.m. CT / 9 a.m. ET
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Integrative biomarkers analysis from the Phase 3 CheckMate 914 trial of nivolumab plus ipilimumab or nivolumab versus placebo for adjuvant clear cell renal cell carcinoma (ccRCC) (Exhibit Halls AB - George R. Brown Convention Center) - Oct 4, 2024 - Abstract #SITC2024SITC_1600;
Full Regular Abstract, Young Investigator Award (YIA), Immune Engineering Abstracts, and Late-breaking Abstract - Clinical Only (LBA) content will be embargoed until Nov. 5, 2024 at 8 a.m. CT / 9 a.m. ET
- BT7480 / Bicycle Therap
Mechanistic biomarker analyses following administration of BT7480, a novel Nectin-4/CD137 Bicycle tumor-targeted immune cell agonist (Exhibit Halls AB - George R. Brown Convention Center) - Oct 4, 2024 - Abstract #SITC2024SITC_1589;
Full Regular Abstract, Young Investigator Award (YIA), Immune Engineering Abstracts, and Late-breaking Abstract - Clinical Only (LBA) content will be embargoed until Nov. 5, 2024 at 8 a.m. CT / 9 a.m. ET
- Opdivo (nivolumab) / BMS
Serum Analytes Associate with Clinical Outcomes in Patients with Triple Negative Breast Cancer Enrolled in the OXEL Trial Treated with Nivolumab, Capecitabine, or their Combination (Exhibit Halls AB - George R. Brown Convention Center) - Oct 4, 2024 - Abstract #SITC2024SITC_1585;
Full Regular Abstract, Young Investigator Award (YIA), Immune Engineering Abstracts, and Late-breaking Abstract - Clinical Only (LBA) content will be embargoed until Nov. 5, 2024 at 8 a.m. CT / 9 a.m. ET
- Epidaza (chidamide) / Chipscreen, Opdivo (nivolumab) / BMS
HBI-8000, a class I histone deacetylase (HDAC) inhibitor, in combination with nivolumab for treatment of anti-PD(L)1-naive advanced melanoma: final analysis of Study HBI-8000-302 (George R. Brown Convention Center - Level 3 - Grand Ballroom B) - Oct 4, 2024 - Abstract #SITC2024SITC_1521;
- Opdivo (nivolumab) / BMS
Oncolytic virotherapy combined with Nivolumab elicits complete responses in muscle-invasive bladder cancer in association with the formation of tertiary lymphoid structures (George R. Brown Convention Center - Level 3 - Grand Ballroom C) - Oct 4, 2024 - Abstract #SITC2024SITC_1511;
- Libtayo (cemiplimab-rwlc) / Regeneron
GLIMMER-01: Phase 1/2 trial of a first-in-class bi-sialidase (E-602) in combination with cemiplimab in patients with PD-(L)1-resistant solid tumors (George R. Brown Convention Center - Level 3 - Grand Ballroom C) - Oct 4, 2024 - Abstract #SITC2024SITC_1508;
- IMA203CD8 / Immatics
Enhanced pharmacology data of next-generation IMA203CD8 TCR-T monotherapy targeting PRAME (George R. Brown Convention Center - Level 3 - Grand Ballroom C) - Oct 4, 2024 - Abstract #SITC2024SITC_1507;
- Keytruda (pembrolizumab) / Merck (MSD)
Artificial Intelligence-powered assessment of tumor microenvironment in pre-treatment and on-treatment biopsies informs treatment outcomes to pembrolizumab in patients with rare tumors. (George R. Brown Convention Center - Level 3 - Grand Ballroom C) - Oct 4, 2024 - Abstract #SITC2024SITC_1506;
- Imfinzi (durvalumab) / AstraZeneca
Metacellular Networks and Proteomic Ecotypes Predict Survival Outcomes in HNSCC Treated with Post-operative Radiation Therapy and Durvalumab (George R. Brown Convention Center - Level 3 - Grand Ballroom B) - Oct 4, 2024 - Abstract #SITC2024SITC_1495;
- Keytruda (pembrolizumab) / Merck (MSD), Jemperli (dostarlimab-gxly) / GSK
Updated overall survival from PERLA, a phase II randomized double-blind trial of dostarlimab + chemotherapy (CT) vs pembrolizumab + CT in metastatic non-squamous non-small cell lung cancer (NSCLC) (George R. Brown Convention Center - Level 3 - Grand Ballroom C) - Oct 4, 2024 - Abstract #SITC2024SITC_1483;
- Keytruda (pembrolizumab) / Merck (MSD), CUE-101 / Cue Biopharma, LG Chem
A phase 1 dose-escalation and expansion study of CUE-101 as monotherapy and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck squamous cell cancer (George R. Brown Convention Center - Level 3 - Grand Ballroom C) - Oct 4, 2024 - Abstract #SITC2024SITC_1478;
- Imlygic (talimogene laherparepvec) / Amgen, Opdivo (nivolumab) / BMS
Interim Analysis of a Phase II Study of Talimogene Laherparepvec (T-VEC) Followed by Combination T-VEC + Nivolumab in Non-Melanoma Skin Cancers and Refractory Cutaneous Lymphoma (NCI#10057) (Exhibit Halls AB - George R. Brown Convention Center) - Oct 4, 2024 - Abstract #SITC2024SITC_1470;
Full Regular Abstract, Young Investigator Award (YIA), Immune Engineering Abstracts, and Late-breaking Abstract - Clinical Only (LBA) content will be embargoed until Nov. 5, 2024 at 8 a.m. CT / 9 a.m. ET
- Keytruda (pembrolizumab) / Merck (MSD), Ad-CCL21-DC / National Cancer Institute
Phase I trial of in situ vaccination with autologous CCL21 gene-modified dendritic cells (CCL21-DC) combined with pembrolizumab for metastatic NSCLC (Exhibit Halls AB - George R. Brown Convention Center) - Oct 4, 2024 - Abstract #SITC2024SITC_1461;
Full Regular Abstract, Young Investigator Award (YIA), Immune Engineering Abstracts, and Late-breaking Abstract - Clinical Only (LBA) content will be embargoed until Nov. 5, 2024 at 8 a.m. CT / 9 a.m. ET
- Imfinzi (durvalumab) / AstraZeneca, vactosertib (TEW-7197) / National OncoVenture, Theragen Etex
Vactosertib, a TGF-? signaling inhibitor, in combination with Durvalumab increased mOS in ?2L treatment of patients with PD-L1-positive advanced NSCLC (Exhibit Halls AB - George R. Brown Convention Center) - Oct 4, 2024 - Abstract #SITC2024SITC_1424;
Full Regular Abstract, Young Investigator Award (YIA), Immune Engineering Abstracts, and Late-breaking Abstract - Clinical Only (LBA) content will be embargoed until Nov. 5, 2024 at 8 a.m. CT / 9 a.m. ET
- BH3120 / Hanmi
A Phase I, Open-Label, Multinational, Multicenter, Dose Escalation and Expansion Study of BH3120 (4-1BB x PD-L1 BsAb) in Patients with Advanced or Metastatic Solid Tumors (Exhibit Halls AB - George R. Brown Convention Center) - Oct 4, 2024 - Abstract #SITC2024SITC_1396;
Full Regular Abstract, Young Investigator Award (YIA), Immune Engineering Abstracts, and Late-breaking Abstract - Clinical Only (LBA) content will be embargoed until Nov. 5, 2024 at 8 a.m. CT / 9 a.m. ET
- IO102-IO103 / IO Biotech, Keytruda (pembrolizumab) / Merck (MSD)
A phase 2 trial of the IO102-IO103 cancer vaccine plus pembrolizumab: results from the first-line (1L) cohort of PD-L1 high metastatic non-small cell lung cancer (NSCLC) (Exhibit Halls AB - George R. Brown Convention Center) - Oct 4, 2024 - Abstract #SITC2024SITC_1379;
Full Regular Abstract, Young Investigator Award (YIA), Immune Engineering Abstracts, and Late-breaking Abstract - Clinical Only (LBA) content will be embargoed until Nov. 5, 2024 at 8 a.m. CT / 9 a.m. ET
- Libtayo (cemiplimab-rwlc) / Regeneron, fianlimab (REGN3767) / Regeneron
An early phase expansion cohort study of fianlimab (anti (Exhibit Halls AB - George R. Brown Convention Center) - Oct 4, 2024 - Abstract #SITC2024SITC_1374;
Full Regular Abstract, Young Investigator Award (YIA), Immune Engineering Abstracts, and Late-breaking Abstract - Clinical Only (LBA) content will be embargoed until Nov. 5, 2024 at 8 a.m. CT / 9 a.m. ET
- MK-6070 / Merck (MSD), Daiichi Sankyo
A phase 1/2 trial in progress of MK-6070 (aka HPN328), a DLL3-targeting T cell engager, as monotherapy or combination therapy for advanced cancers associated with DLL3 expression (Exhibit Halls AB - George R. Brown Convention Center) - Oct 4, 2024 - Abstract #SITC2024SITC_1352;
Full Regular Abstract, Young Investigator Award (YIA), Immune Engineering Abstracts, and Late-breaking Abstract - Clinical Only (LBA) content will be embargoed until Nov. 5, 2024 at 8 a.m. CT / 9 a.m. ET
- nivolumab subcutaneous (BMS-986298) / BMS, Ono Pharma
Novel model-based approach to support clinical pharmacology profiling of subcutaneous (SC) nivolumab in renal-cell carcinoma and bridging to alternative SC dosing regimens and solid tumor indications (Exhibit Halls AB - George R. Brown Convention Center) - Oct 4, 2024 - Abstract #SITC2024SITC_1285;
Full Regular Abstract, Young Investigator Award (YIA), Immune Engineering Abstracts, and Late-breaking Abstract - Clinical Only (LBA) content will be embargoed until Nov. 5, 2024 at 8 a.m. CT / 9 a.m. ET
- Keytruda (pembrolizumab) / Merck (MSD)
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1 ?50% treated with first line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry (Exhibit Halls AB - George R. Brown Convention Center) - Oct 4, 2024 - Abstract #SITC2024SITC_1284;
Full Regular Abstract, Young Investigator Award (YIA), Immune Engineering Abstracts, and Late-breaking Abstract - Clinical Only (LBA) content will be embargoed until Nov. 5, 2024 at 8 a.m. CT / 9 a.m. ET
- ALG.APV-527 / Alligator Biosci, Aptevo Therap
Preliminary results from a phase I dose escalation study of ALG.APV-527, a 5T4 x 4-1BB bispecific antibody, in patients with advanced solid tumors demonstrate favorable safety and biological activity (Exhibit Halls AB - George R. Brown Convention Center) - Oct 4, 2024 - Abstract #SITC2024SITC_1281;
Full Regular Abstract, Young Investigator Award (YIA), Immune Engineering Abstracts, and Late-breaking Abstract - Clinical Only (LBA) content will be embargoed until Nov. 5, 2024 at 8 a.m. CT / 9 a.m. ET
- IPH6501 / Innate
Preclinical Characterization of IPH6501: A Novel IL2v-Armed Tetraspecific NK Cell Engager Targeting CD20 in Relapsed or Refractory B cell Non-Hodgkin Lymphoma Subtypes and Post-CAR-T Therapy. (Exhibit Halls AB - George R. Brown Convention Center) - Oct 4, 2024 - Abstract #SITC2024SITC_1241;
Full Regular Abstract, Young Investigator Award (YIA), Immune Engineering Abstracts, and Late-breaking Abstract - Clinical Only (LBA) content will be embargoed until Nov. 5, 2024 at 8 a.m. CT / 9 a.m. ET
- Keytruda (pembrolizumab) / Merck (MSD)
A Phase 2 Feasibility Study Combining Pembrolizumab and Metformin to Harness the Natural Killer Cytotoxic Response in Metastatic Head and Neck Cancer Patients (Exhibit Halls AB - George R. Brown Convention Center) - Oct 4, 2024 - Abstract #SITC2024SITC_1240;
Full Regular Abstract, Young Investigator Award (YIA), Immune Engineering Abstracts, and Late-breaking Abstract - Clinical Only (LBA) content will be embargoed until Nov. 5, 2024 at 8 a.m. CT / 9 a.m. ET
- Imfinzi (durvalumab) / AstraZeneca
Differential Gene Enrichment in Response to Durvalumab and Metformin in Head and Neck Cancer Patients: The Role of the Neutrophil to Lymphocyte Ratio (NLR) and Epithelial Mesenchymal Transition (EMT) (Exhibit Halls AB - George R. Brown Convention Center) - Oct 4, 2024 - Abstract #SITC2024SITC_1133;
Full Regular Abstract, Young Investigator Award (YIA), Immune Engineering Abstracts, and Late-breaking Abstract - Clinical Only (LBA) content will be embargoed until Nov. 5, 2024 at 8 a.m. CT / 9 a.m. ET
- Keytruda (pembrolizumab) / Merck (MSD)
Comparative Analysis of Pembrolizumab Dosing Schedules in the Adjuvant Treatment of Malignant Melanoma: A Real-World Experience of 6 Weeks Versus 3 Weeks (Exhibit Halls AB - George R. Brown Convention Center) - Oct 4, 2024 - Abstract #SITC2024SITC_1125;
Full Regular Abstract, Young Investigator Award (YIA), Immune Engineering Abstracts, and Late-breaking Abstract - Clinical Only (LBA) content will be embargoed until Nov. 5, 2024 at 8 a.m. CT / 9 a.m. ET
- SOT-201 / Sotio
SOT201, a novel cis-acting PD-1/IL-15 mutein-based immunocytokine that reinvigorates anti-tumor immunity qualitatively superior to PD-1/IL-2v-based IL-2/15R?? agonism (Exhibit Halls AB - George R. Brown Convention Center) - Oct 4, 2024 - Abstract #SITC2024SITC_1086;
Full Regular Abstract, Young Investigator Award (YIA), Immune Engineering Abstracts, and Late-breaking Abstract - Clinical Only (LBA) content will be embargoed until Nov. 5, 2024 at 8 a.m. CT / 9 a.m. ET
- STK-012 / Synthekine
T cell and Immune Activation from a Phase 1 Study of STK-012, a First-in-class IL-2R ?/? Selective Partial Agonist in Advanced Solid Tumors (Exhibit Halls AB - George R. Brown Convention Center) - Oct 4, 2024 - Abstract #SITC2024SITC_1084;
Full Regular Abstract, Young Investigator Award (YIA), Immune Engineering Abstracts, and Late-breaking Abstract - Clinical Only (LBA) content will be embargoed until Nov. 5, 2024 at 8 a.m. CT / 9 a.m. ET
- Keytruda (pembrolizumab) / Merck (MSD), Hyleukin-7 (efineptakin alfa) / Genexine, NeoImmuneTech
A biomarker signature differentiates immune status in patients with cold gastrointestinal tumors, predicting clinical benefit of NT-I7 (efineptakin alfa, a long-acting interleukin-7) and pembrolizumab (Exhibit Halls AB - George R. Brown Convention Center) - Oct 4, 2024 - Abstract #SITC2024SITC_1058;
Full Regular Abstract, Young Investigator Award (YIA), Immune Engineering Abstracts, and Late-breaking Abstract - Clinical Only (LBA) content will be embargoed until Nov. 5, 2024 at 8 a.m. CT / 9 a.m. ET
- EVOLVE-104 / EvolveImmune Therap
EVOLVE104, a first-in-class ULBP2/5/6-targeting T-cell engager with integrated CD2 co-stimulation, demonstrates a favorable preclinical safety and toxicity profile in cynomolgus monkeys (Exhibit Halls AB - George R. Brown Convention Center) - Oct 4, 2024 - Abstract #SITC2024SITC_1050;
Full Regular Abstract, Young Investigator Award (YIA), Immune Engineering Abstracts, and Late-breaking Abstract - Clinical Only (LBA) content will be embargoed until Nov. 5, 2024 at 8 a.m. CT / 9 a.m. ET
- brenetafusp (IMC-F106C) / Immunocore
Phase 1 safety and efficacy of brenetafusp, a PRAME (Exhibit Halls AB - George R. Brown Convention Center) - Oct 4, 2024 - Abstract #SITC2024SITC_1045;
Full Regular Abstract, Young Investigator Award (YIA), Immune Engineering Abstracts, and Late-breaking Abstract - Clinical Only (LBA) content will be embargoed until Nov. 5, 2024 at 8 a.m. CT / 9 a.m. ET
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Phase 2 study of nivolumab and ipilimumab in combination with sirolimus and prednisone in kidney transplant recipients with selected unresectable or metastatic cutaneous cancers (Exhibit Halls AB - George R. Brown Convention Center) - Oct 4, 2024 - Abstract #SITC2024SITC_1040;
Full Regular Abstract, Young Investigator Award (YIA), Immune Engineering Abstracts, and Late-breaking Abstract - Clinical Only (LBA) content will be embargoed until Nov. 5, 2024 at 8 a.m. CT / 9 a.m. ET
- MDNA11 / Medicenna
Results from ABILITY-1 monotherapy dose escalation and ongoing monotherapy expansion with MDNA11, a long-acting 'beta-enhanced not-alpha' IL-2 superkine, in patients with advanced solid tumors (Exhibit Halls AB - George R. Brown Convention Center) - Oct 4, 2024 - Abstract #SITC2024SITC_1037;
Full Regular Abstract, Young Investigator Award (YIA), Immune Engineering Abstracts, and Late-breaking Abstract - Clinical Only (LBA) content will be embargoed until Nov. 5, 2024 at 8 a.m. CT / 9 a.m. ET
- Keytruda (pembrolizumab) / Merck (MSD)
Immunoprofiling and correlative analysis from PROTA: A Phase I trial combining an oncolytic adenovirus encoding TNF? and IL2 with pembrolizumab for platinum-resistant or refractory ovarian cancer (Exhibit Halls AB - George R. Brown Convention Center) - Oct 4, 2024 - Abstract #SITC2024SITC_1036;
Full Regular Abstract, Young Investigator Award (YIA), Immune Engineering Abstracts, and Late-breaking Abstract - Clinical Only (LBA) content will be embargoed until Nov. 5, 2024 at 8 a.m. CT / 9 a.m. ET
- Keytruda (pembrolizumab) / Merck (MSD), NDI-101150 / Nimbus Therap
Ongoing phase 1/2 trial of the HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab: clinical safety update and renal cell carcinoma (RCC) efficacy analysis (Exhibit Halls AB - George R. Brown Convention Center) - Oct 4, 2024 - Abstract #SITC2024SITC_1033;
Full Regular Abstract, Young Investigator Award (YIA), Immune Engineering Abstracts, and Late-breaking Abstract - Clinical Only (LBA) content will be embargoed until Nov. 5, 2024 at 8 a.m. CT / 9 a.m. ET
- Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD), Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
Combination Immunotherapy with pembrolizumab, lenvatinib, N-803 and dendritic cell vaccine targeting HER2 in patients with advanced or metastatic endometrial cancer (Exhibit Halls AB - George R. Brown Convention Center) - Oct 4, 2024 - Abstract #SITC2024SITC_1031;
Full Regular Abstract, Young Investigator Award (YIA), Immune Engineering Abstracts, and Late-breaking Abstract - Clinical Only (LBA) content will be embargoed until Nov. 5, 2024 at 8 a.m. CT / 9 a.m. ET
- Keytruda (pembrolizumab) / Merck (MSD), TEV-'278 / Teva
A first-in-human study evaluating safety, tolerability and efficacy of TEV-56278, as monotherapy and in combination with pembrolizumab in participants with locally advanced or metastatic solid tumors (Exhibit Halls AB - George R. Brown Convention Center) - Oct 4, 2024 - Abstract #SITC2024SITC_1030;
Full Regular Abstract, Young Investigator Award (YIA), Immune Engineering Abstracts, and Late-breaking Abstract - Clinical Only (LBA) content will be embargoed until Nov. 5, 2024 at 8 a.m. CT / 9 a.m. ET
- WTX212 / Westlake Therap
Erythrocyte-?PD-1 conjugates suppress cancers with resistance to checkpoint blockade immunotherapy (Exhibit Halls AB - George R. Brown Convention Center) - Oct 4, 2024 - Abstract #SITC2024SITC_1027;
Full Regular Abstract, Young Investigator Award (YIA), Immune Engineering Abstracts, and Late-breaking Abstract - Clinical Only (LBA) content will be embargoed until Nov. 5, 2024 at 8 a.m. CT / 9 a.m. ET